Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Organovo Holdings, Inc. - Common Stock (NQ:ONVO)

2.040 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organovo Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
These stocks are the most active in today's session
Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today. 
Via Chartmill
Which stocks are experiencing notable movement on Tuesday?
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Nasdaq Dips 1.5%; Home Depot Issues Weak Forecast
Via Benzinga
Why Eli Lilly Stock Popped Today
Via The Motley Fool
Traders are paying attention to the gapping stocks in Tuesday's session.
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Why Organovo (ONVO) Stock Is Skyrocketing
Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR program, including FXR314. 
Via Benzinga
What's going on in today's pre-market session
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
From Organovo, Inc.
Via GlobeNewswire
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
From Organovo, Inc.
Via GlobeNewswire
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
From Organovo, Inc.
Via GlobeNewswire
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
From Organovo, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
Via Benzinga
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
From Organovo, Inc.
Via GlobeNewswire
ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024
ONVO stock results show that Organovo Holdings beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. 
Via InvestorPlace
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
From Organovo, Inc.
Via GlobeNewswire
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024 
From Organovo, Inc.
Via GlobeNewswire
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday! 
Via InvestorPlace
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
From Organovo, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Organovo Stock Is Up Today
Organovo released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic... 
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
From Organovo, Inc.
Via GlobeNewswire
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
From Organovo, Inc.
Via GlobeNewswire
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
From Organovo, Inc.
Via GlobeNewswire
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
From Organovo, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.